Meeder Asset Management Inc Genprex, Inc. Transaction History

Meeder Asset Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.76 - $1.78 $6,766 - $15,847	-8,903 Reduced 97.05%	271 $0
Q4 2022 Feb 14, 2023	SELL	$1.0 - $58.8 $1,467 - $86,259	-1,467 Reduced 13.79%	9,174 $13,000
Q2 2022 Aug 08, 2022	SELL	$1.28 - $2.31 $44 - $80	-35 Reduced 0.33%	10,641 $14,000
Q1 2022 May 10, 2022	BUY	$1.82 - $3.5 $19,430 - $37,366	10,676 New	10,676 $23,000
Q4 2021 Feb 11, 2022	SELL	$1.21 - $2.7 $12,815 - $28,595	-10,591 Closed	0 $0
Q1 2021 Apr 28, 2021	BUY	$3.66 - $7.67 $38,763 - $81,232	10,591 New	10,591 $45,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $76.8M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.